search
Back to results

ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation (ENVISION)

Primary Purpose

Aortic Valve Stenosis, Heart Valve Diseases, Aortic Valve Disease

Status
Not yet recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Navitor Transcatheter Aortic Valve Implantation (TAVI) System
Any Commercially Available Transcatheter Aortic Valve (CAV) System
Sponsored by
Abbott Medical Devices
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Aortic Valve Stenosis focused on measuring NAVITOR, Heart disease, Transcatheter aortic valve implantation (TAVI), Aortic stenosis, Cardiovascular diseases

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria: Subject who is deemed to be at intermediate or low risk for open surgical aortic valve replacement: Intermediate risk: estimated risk of overall surgical mortality ≥ 3% and < 8% at 30 days Low risk: estimated risk of overall surgical mortality < 3% at 30 days Estimated risk of overall surgical mortality includes consideration of the Society of Thoracic Surgeons (STS) risk score, overall clinical status, and other clinical co-morbidities unmeasured by the risk calculator New York Heart Association (NYHA) Functional Classification of II, III, or IV Degenerative aortic valve stenosis Key Exclusion Criteria: In the opinion of the Investigator, life expectancy is less than 2 years Evidence of an acute myocardial infarction [defined as ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) with acute ischemia symptoms and troponin elevation] within 30 days prior to index procedure Untreated clinically significant coronary artery disease requiring revascularization Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior (except pacemaker or implantable cardioverter defibrillator (ICD) implant) to index procedure or planned within 30 days following the index procedure Blood dyscrasias as defined: leukopenia (WBC < 3000 mm3), acute anemia (Hb < 9 g/dL), thrombocytopenia (platelet count < 50,000 cells/mm³); history of bleeding diathesis or coagulopathy Active peptic ulcer or upper GI bleeding within 3 months prior to index procedure that would preclude anticoagulation Recent (within 6 months prior to index procedure date) cerebrovascular accident (CVA) or a transient ischemic attack (TIA) Renal insufficiency (creatinine > 3.0 mg/dL or eGFR < 30 ml/min/1.73m2) and/or end stage renal disease requiring chronic dialysis Hostile chest or conditions or complications from prior surgery that would make the subject be considered high surgical risk (i.e., mediastinitis, radiation damage, abnormal chest wall, porcelain aorta, adhesion of aorta or internal mammary artery to sternum, etc.) Significant frailty as determined by the heart team (after objective assessment of frailty parameters) that would indicate high or extreme surgical risk Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation 3-4+) Aortic valve is a unicuspid or bicuspid valve as verified by echocardiography or CT. Severe ventricular dysfunction with LVEF < 30% as measured by resting echocardiogram Pre-existing prosthetic heart valve or other implant (such as prosthetic ring or transcatheter edge-to-edge repair (TEER) clip) in any valve position Severe circumferential mitral annular calcification (MAC) which is continuous with calcium in the left ventricular outflow tract (LVOT) Severe (greater than or equal to 3+) mitral regurgitation or severe mitral stenosis Minimum access vessel diameter of < 5.0 mm for small FlexNav Delivery System and < 5.5 mm for large FlexNav Delivery System Eccentricity ratio of the annulus < 0.73

Sites / Locations

  • Arkansas Heart Hospital
  • Los Robles Regional Medical Center
  • Cardiovascular Research Institute of Kansas
  • Baptist Memorial Hospital
  • The Methodist Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Navitor Transcatheter Aortic Valve Implantation (TAVI) System

Any Commercially Available Transcatheter Aortic Valve System (CAV)

Arm Description

TAVI with Abbott Navitor Transcatheter Aortic Valve Implantation (TAVI) System

TAVI with any FDA approved commercially available Transcatheter Aortic Valve System (CAV)

Outcomes

Primary Outcome Measures

Composite of all-cause mortality or all stroke
Number of patients that had any of the outcome events.

Secondary Outcome Measures

Full Information

First Posted
June 27, 2023
Last Updated
October 21, 2023
Sponsor
Abbott Medical Devices
search

1. Study Identification

Unique Protocol Identification Number
NCT05932615
Brief Title
ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation
Acronym
ENVISION
Official Title
Evaluation of the Navitor Transcatheter Heart Valve in Low and Intermediate Risk Patients Who Have Severe, Symptomatic, Aortic Stenosis Requiring Aortic Valve Replacement
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
November 2023 (Anticipated)
Primary Completion Date
April 2027 (Anticipated)
Study Completion Date
April 2036 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Abbott Medical Devices

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The objective of ENVISION is to evaluate the safety and effectiveness of the Navitor Transcatheter Aortic Valve Implantation (TAVI) System for treating patients with symptomatic, severe native aortic stenosis who are considered intermediate or low risk for surgical mortality.
Detailed Description
ENVISION is a prospective, randomized controlled, multi-center clinical investigation that will randomize up to 1300 subjects at up to 80 sites in the U.S. and Canada. The objective of this clinical investigation is to evaluate the safety and effectiveness of the Navitor TAVI System for treating patients with symptomatic, severe native aortic stenosis who are considered intermediate or low risk for surgical mortality. Subjects in this clinical investigation will be randomized between the Navitor TAVI Implantation System (test arm) and any commercially available transcatheter aortic valve system (CAV) (control arm) in a 1:1 ratio.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Aortic Valve Stenosis, Heart Valve Diseases, Aortic Valve Disease, Heart Disease Structural Disorder
Keywords
NAVITOR, Heart disease, Transcatheter aortic valve implantation (TAVI), Aortic stenosis, Cardiovascular diseases

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1300 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Navitor Transcatheter Aortic Valve Implantation (TAVI) System
Arm Type
Experimental
Arm Description
TAVI with Abbott Navitor Transcatheter Aortic Valve Implantation (TAVI) System
Arm Title
Any Commercially Available Transcatheter Aortic Valve System (CAV)
Arm Type
Active Comparator
Arm Description
TAVI with any FDA approved commercially available Transcatheter Aortic Valve System (CAV)
Intervention Type
Device
Intervention Name(s)
Navitor Transcatheter Aortic Valve Implantation (TAVI) System
Intervention Description
TAVI for relief of calcific aortic stenosis in patients with symptomatic heart disease who are at intermediate or low risk for open surgical therapy.
Intervention Type
Device
Intervention Name(s)
Any Commercially Available Transcatheter Aortic Valve (CAV) System
Intervention Description
TAVI for relief of calcific aortic stenosis in patients with symptomatic heart disease who are at intermediate or low risk for open surgical therapy.
Primary Outcome Measure Information:
Title
Composite of all-cause mortality or all stroke
Description
Number of patients that had any of the outcome events.
Time Frame
At 12 months post-procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: Subject who is deemed to be at intermediate or low risk for open surgical aortic valve replacement: Intermediate risk: estimated risk of overall surgical mortality ≥ 3% and < 8% at 30 days Low risk: estimated risk of overall surgical mortality < 3% at 30 days Estimated risk of overall surgical mortality includes consideration of the Society of Thoracic Surgeons (STS) risk score, overall clinical status, and other clinical co-morbidities unmeasured by the risk calculator New York Heart Association (NYHA) Functional Classification of II, III, or IV Degenerative aortic valve stenosis Key Exclusion Criteria: In the opinion of the Investigator, life expectancy is less than 2 years Evidence of an acute myocardial infarction [defined as ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) with acute ischemia symptoms and troponin elevation] within 30 days prior to index procedure Untreated clinically significant coronary artery disease requiring revascularization Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior (except pacemaker or implantable cardioverter defibrillator (ICD) implant) to index procedure or planned within 30 days following the index procedure Blood dyscrasias as defined: leukopenia (WBC < 3000 mm3), acute anemia (Hb < 9 g/dL), thrombocytopenia (platelet count < 50,000 cells/mm³); history of bleeding diathesis or coagulopathy Active peptic ulcer or upper GI bleeding within 3 months prior to index procedure that would preclude anticoagulation Recent (within 6 months prior to index procedure date) cerebrovascular accident (CVA) or a transient ischemic attack (TIA) Renal insufficiency (creatinine > 3.0 mg/dL or eGFR < 30 ml/min/1.73m2) and/or end stage renal disease requiring chronic dialysis Hostile chest or conditions or complications from prior surgery that would make the subject be considered high surgical risk (i.e., mediastinitis, radiation damage, abnormal chest wall, porcelain aorta, adhesion of aorta or internal mammary artery to sternum, etc.) Significant frailty as determined by the heart team (after objective assessment of frailty parameters) that would indicate high or extreme surgical risk Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation 3-4+) Aortic valve is a unicuspid or bicuspid valve as verified by echocardiography or CT. Severe ventricular dysfunction with LVEF < 30% as measured by resting echocardiogram Pre-existing prosthetic heart valve or other implant (such as prosthetic ring or transcatheter edge-to-edge repair (TEER) clip) in any valve position Severe circumferential mitral annular calcification (MAC) which is continuous with calcium in the left ventricular outflow tract (LVOT) Severe (greater than or equal to 3+) mitral regurgitation or severe mitral stenosis Minimum access vessel diameter of < 5.0 mm for small FlexNav Delivery System and < 5.5 mm for large FlexNav Delivery System Eccentricity ratio of the annulus < 0.73
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sara Scrivano
Phone
623-256-9821
Email
sara.scrivano@abbott.com
First Name & Middle Initial & Last Name or Official Title & Degree
Hai-Chien Kuo
Phone
408-221-6366
Email
hai-chien.kuo@abbott.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Reardon, MD
Organizational Affiliation
The Methodist Hospital Research Institute
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Azeem Latib, MD
Organizational Affiliation
Montefiore Medical Center
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Vinny Podichetty
Organizational Affiliation
Abbott Structural Heart
Official's Role
Study Director
Facility Information:
Facility Name
Arkansas Heart Hospital
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72211
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
William A Rollefson, MD
First Name & Middle Initial & Last Name & Degree
William A Rollefson, MD
Facility Name
Los Robles Regional Medical Center
City
Thousand Oaks
State/Province
California
ZIP/Postal Code
91360
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gregory Fontana, M.D.
First Name & Middle Initial & Last Name & Degree
Gregory Fontana, M.D.
Facility Name
Cardiovascular Research Institute of Kansas
City
Wichita
State/Province
Kansas
ZIP/Postal Code
67226
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bassem Chehab, M.D.
First Name & Middle Initial & Last Name & Degree
Bassem Chehab, M.D.
Facility Name
Baptist Memorial Hospital
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38120
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Basil Paulus, MD
First Name & Middle Initial & Last Name & Degree
Basil Paulus, MD
Facility Name
The Methodist Hospital
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marvin Atkins, MD
First Name & Middle Initial & Last Name & Degree
Marvin Atkins, MD

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
There is not a plan to make IPD available to other researhers.

Learn more about this trial

ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation

We'll reach out to this number within 24 hrs